News

Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current

This is the second product Clinigen has licensed to Cumberland under the strategic alliance established in 2015, following the launch of Ethyol (amifostine) in the U.S. in September 2016.

The company acquired about 8.4 percent of the outstanding shares of common stock in Arrowhead Since the capital raise of May 2015, Silence has been actively evaluating a

Under the terms of the deal, which is expected to close by the end of next month, Takeda agreed to pay $24 in cash for each Ariad share.

Subject to stockholder approval, the combined company will advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product

Amgen which filed the lawsuit against the joint developers of Praulent got the injunction in its favor in the US District Court in Delaware. The California based company

Lucentis is the first FDA-approved anti-vascular endothelial growth factor (VEGF) therapy to treat mCNV in the U.S. This is the fifth FDA-approved indication for Lucentis since the medicine

PNH is a debilitating, ultra-rare, life-threatening blood disorder in which uncontrolled activation of complement, a component of the immune system, results in hemolysis (destruction of a patient’s red

The Swiss drugmaker signed a collaboration and option agreement, which is subject to customary closing conditions and regulatory approvals. Ionis developed two investigational antisense therapies, dubbed AKCEA-APO(a)-LRx and